Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1091]
News [2724]
Articles [183]
Editorials [9]
Conferences [110]
elearning [25]

Bladder cancer updates from the first half of 2026

Prof Alison Birtle, Dr Ignacio Duran, Dr Laura Mertens, Prof Morgan Rouprêt and Dr Patrizia Giannatempo
Bladder cancer updates from the first half of 2026 ( Prof Alison Birtle, Dr Ignacio Duran, Dr Laura Mertens, Prof Morgan Rouprêt and Dr Patrizia Giannatempo )
31 Jul 2026

The impact of disease burden: Understanding patient priorities in aRCC

Prof Thomas Powles and Dena Battle
The impact of disease burden: Understanding patient priorities in aRCC ( Prof Thomas Powles and Dena Battle )
20 Jul 2026

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

Dr Rahul Aggarwal - University of California, San Francisco, USA
Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC ( Dr Rahul Aggarwal - University of California, San Francisco, USA )
26 Jun 2026

Highlights from APCCC 2026

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
Highlights from APCCC 2026 ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
24 Jun 2026

ASCO 2026: Updates in bladder cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
ASCO 2026: Updates in bladder cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
24 Jun 2026

ASCO 2026: Updates in renal cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
ASCO 2026: Updates in renal cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
23 Jun 2026

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
22 Jun 2026

Understanding patient expectations and clinicians' goals in favourable risk aRCC patients

Prof Daniele Santini and Dr Yann Alexandre Vano
Understanding patient expectations and clinicians' goals in favourable risk aRCC patients ( Prof Daniele Santini and Dr Yann Alexandre Vano )
15 Jun 2026

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA
Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC ( Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA )
9 Jun 2026

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
1 Jun 2026

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger
ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )
1 Jun 2026

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA
177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )
1 Jun 2026

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation